<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388008</url>
  </required_header>
  <id_info>
    <org_study_id>Bela Lung Pilot</org_study_id>
    <nct_id>NCT03388008</nct_id>
  </id_info>
  <brief_title>Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation</brief_title>
  <official_title>A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsey Hachem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot randomized controlled trial examining the feasibility of conducting a large
      scale randomized controlled trial of belatacept-based immunosuppression in lung
      transplantation. This pilot study will enroll 40 lung transplant recipients and randomize
      them to belatacept-based immunosuppression or standard of care. The primary endpoint of the
      study is the development of donor-specific HLA antibodies after transplantation. All study
      participants will be followed for a minimum of 12 months after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplantation is the ultimate treatment for patients with advanced lung disease.
      However, long-term outcomes remain disappointing and the median survival after
      transplantation is approximately 5.5 years. Beyond the first year after transplantation,
      chronic lung allograft dysfunction is the leading cause of death. The exact mechanisms that
      lead to chronic lung allograft dysfunction are unclear, but the development of donor-specific
      HLA antibodies is an independent risk factor. In fact, studies have consistently identified
      the development of donor-specific HLA antibodies as a significant and independent risk factor
      for chronic lung allograft dysfunction and mortality after transplantation.

      Belatacept is a CTLA4-Ig fusion protein that binds CD80 and CD86 thereby blocking CD28
      co-stimulatory signals. Belatacept has been extensively studied in kidney transplantation. In
      a long-term study, patients treated with Belatacept had better survival than those treated
      with Cyclosporine. Importantly, Belatacept-treated patients were significantly less likely to
      develop donor-specific HLA antibodies than Cyclosporine-treated patients. Nonetheless,
      Belatacept has not been formally evaluated after lung transplantation. The investigators
      hypothesize that Belatacept-based immunosuppression would result in a lower incidence of
      donor-specific HLA antibodies and that this would result in better chronic lung allograft
      dysfunction-free survival after transplantation. Before conducting a large scale randomized
      controlled trial to test this hypothesis, the investigators plan to conduct the current pilot
      randomized controlled trial to examine the feasibility of conducting the large scale
      randomized controlled trial.

      The investigators plan to enroll and randomize 40 lung transplant recipients at 2 sites. All
      recipients will be treated with anti-thymocyte globulin for induction immunosuppression.
      Those randomized to standard of care immunosuppression will be treated with Tacrolimus,
      Mycophenolate mofetil, and prednisone. Those randomized to Belatacept-based immunosuppression
      will be treated with Belatacept, Tacrolimus, and prednisone for the first 89 days; on day 90,
      Mycophenolate mofetil will be substituted for Tacrolimus and patients will be continued on
      Belatacept, Mycophenolate mofetil, and prednisone for the remainder of year 1 after
      transplantation.

      Patients in both groups will be monitored closely for episodes of acute cellular rejection,
      lymphocytic bronchiolitis, and antibody-mediated rejection with surveillance bronchoscopy and
      transbronchial lung biopsies on days 28, 84, 112, 168, 252, and 365 (± 7 days) as part of the
      sites' routine clinical protocols. In addition, patients will be monitored for the
      development of donor-specific HLA antibodies with routine blood tests on on days 10 (± 3
      days), 28, 56, 84, 112, 168, 252, and 365 (± 7 days).

      The primary endpoint of the study is a composite of the development of donor-specific HLA
      antibodies, re-transplantation, and death. Secondary endpoints include acute cellular
      rejection, lymphocytic bronchiolitis, antibody-mediated rejection, chronic lung allograft
      dysfunction, survival, cytomegalovirus infection, bacterial infection, community-acquired
      respiratory viral infection, chronic kidney disease stage 3, malignancy, hypertension,
      diabetes, and hypercholesterolemia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study participants will be randomized to 1 of 2 arms: Belatacept-based immunosuppression or standard of care immunosuppression</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Investigators examining lung biopsy results and blood for the development of donor-specific HLA antibodies will be blinded to study participants' treatment arm assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Donor-specific HLA antibodies, re-transplantation, or death</measure>
    <time_frame>365 days</time_frame>
    <description>Composite primary endpoint</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept-based immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)</description>
    <arm_group_label>Belatacept-based immunosuppression</arm_group_label>
    <other_name>Nulojix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml</description>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Belatacept-based immunosuppression</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Belatacept-based immunosuppression</arm_group_label>
    <other_name>Cellcept, Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Belatacept-based immunosuppression</arm_group_label>
    <other_name>Solumedrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Belatacept-based immunosuppression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provided written informed consent for study participation

          -  Underwent single or bilateral lung transplantation

          -  Negative urine pregnancy test for women of child bearing potential and willingness to
             use highly-effective contraception

        Exclusion Criteria:

          -  Requiring invasive mechanical ventilation immediately before transplantation

          -  Requiring extracorporeal life support (ECLS) (i.e., ECMO) immediately before
             transplantation

          -  Received treatment to deplete HLA antibodies before transplantation to improve the
             possibility of transplantation

          -  Having DSA immediately before transplantation (i.e., positive virtual crossmatch)

          -  Listed for multi-organ transplant (e.g., heart-lung, liver-lung, kidney-lung)

          -  Pregnant or breast-feeding

          -  Active infection with Hepatitis B or C virus

          -  Active infection with human immunodeficiency virus (HIV)

          -  Chronic infection with Burkholderia cepacia complex before transplantation

          -  Epstein Barr Virus (EBV) seronegative status

          -  Participation in another interventional clinical trial

          -  Allograft dysfunction requiring ECMO support after transplantation

          -  Delayed chest closure after transplantation

          -  Severe coagulopathy and significant bleeding in the opinion of the PI

          -  Any condition that in the opinion of the site PI introduces undue risk by
             participating in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramsey R Hachem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramsey R Hachem, MD</last_name>
    <phone>(314) 454-8766</phone>
    <email>Rhachem@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katina Richardson</last_name>
    <phone>(314) 454-8766</phone>
    <email>k.richardson@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baylor University Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Howard Huang, MD</last_name>
      <phone>214-820-7856</phone>
      <email>Howard.Huang@BSWHealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, Levvey BJ, Lund LH, Meiser B, Rossano JW, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015 Oct;34(10):1264-77. doi: 10.1016/j.healun.2015.08.014. Epub 2015 Sep 3.</citation>
    <PMID>26454740</PMID>
  </reference>
  <reference>
    <citation>Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002 Mar;21(3):297-310. Review.</citation>
    <PMID>11897517</PMID>
  </reference>
  <reference>
    <citation>Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014 Feb;33(2):127-33. doi: 10.1016/j.healun.2013.10.022. Epub 2013 Oct 24.</citation>
    <PMID>24374027</PMID>
  </reference>
  <reference>
    <citation>Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014 Dec;44(6):1479-503. doi: 10.1183/09031936.00107514. Epub 2014 Oct 30.</citation>
    <PMID>25359357</PMID>
  </reference>
  <reference>
    <citation>Lama VN, Murray S, Lonigro RJ, Toews GB, Chang A, Lau C, Flint A, Chan KM, Martinez FJ. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med. 2007 Jun 1;175(11):1192-8. Epub 2007 Mar 8.</citation>
    <PMID>17347496</PMID>
  </reference>
  <reference>
    <citation>Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med. 2010 Sep 15;182(6):784-9. doi: 10.1164/rccm.201002-0211OC. Epub 2010 May 27.</citation>
    <PMID>20508211</PMID>
  </reference>
  <reference>
    <citation>Singer JP, Singer LG. Quality of life in lung transplantation. Semin Respir Crit Care Med. 2013 Jun;34(3):421-30. doi: 10.1055/s-0033-1348470. Epub 2013 Jul 2. Review.</citation>
    <PMID>23821515</PMID>
  </reference>
  <reference>
    <citation>Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, Patterson GA, Trulock EP, Hachem RR. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007 Mar 1;175(5):507-13. Epub 2006 Dec 7.</citation>
    <PMID>17158279</PMID>
  </reference>
  <reference>
    <citation>Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008 May 1;177(9):1033-40. doi: 10.1164/rccm.200706-951OC. Epub 2008 Feb 8.</citation>
    <PMID>18263803</PMID>
  </reference>
  <reference>
    <citation>Hachem RR, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005 Nov 27;80(10):1406-13.</citation>
    <PMID>16340783</PMID>
  </reference>
  <reference>
    <citation>Le Pavec J, Suberbielle C, Lamrani L, Feuillet S, Savale L, Dorfmüller P, Stephan F, Mussot S, Mercier O, Fadel E. De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome. J Heart Lung Transplant. 2016 Sep;35(9):1067-77. doi: 10.1016/j.healun.2016.05.020. Epub 2016 May 31.</citation>
    <PMID>27373824</PMID>
  </reference>
  <reference>
    <citation>Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation. Am J Respir Crit Care Med. 2016 Sep 1;194(5):596-606. doi: 10.1164/rccm.201509-1857OC.</citation>
    <PMID>26967790</PMID>
  </reference>
  <reference>
    <citation>Girnita AL, McCurry KR, Iacono AT, Duquesnoy R, Corcoran TE, Awad M, Spichty KJ, Yousem SA, Burckart G, Dauber JH, Griffith BP, Zeevi A. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant. 2004 Oct;23(10):1135-41.</citation>
    <PMID>15477106</PMID>
  </reference>
  <reference>
    <citation>Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, Griffith BP, McCurry KR, Zeevi A. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant. 2005 Jan;5(1):131-8.</citation>
    <PMID>15636621</PMID>
  </reference>
  <reference>
    <citation>Bharat A, Kuo E, Steward N, Aloush A, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg. 2008 Jul;86(1):189-95; discussion 196-7. doi: 10.1016/j.athoracsur.2008.03.073.</citation>
    <PMID>18573422</PMID>
  </reference>
  <reference>
    <citation>Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol. 2003 May;64(5):521-9.</citation>
    <PMID>12691702</PMID>
  </reference>
  <reference>
    <citation>Maruyama T, Jaramillo A, Narayanan K, Higuchi T, Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant. 2005 Sep;5(9):2126-34.</citation>
    <PMID>16095491</PMID>
  </reference>
  <reference>
    <citation>Fukami N, Ramachandran S, Saini D, Walter M, Chapman W, Patterson GA, Mohanakumar T. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol. 2009 Jan 1;182(1):309-18.</citation>
    <PMID>19109162</PMID>
  </reference>
  <reference>
    <citation>Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, Ratner LE, Cohen DJ, Radhakrishnan J. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol. 2012 Dec;23(12):2061-71. doi: 10.1681/ASN.2012070664. Epub 2012 Nov 15. Review.</citation>
    <PMID>23160511</PMID>
  </reference>
  <reference>
    <citation>Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005 Aug 25;353(8):770-81.</citation>
    <PMID>16120857</PMID>
  </reference>
  <reference>
    <citation>Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x.</citation>
    <PMID>20415897</PMID>
  </reference>
  <reference>
    <citation>Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012 Jan;12(1):210-7. doi: 10.1111/j.1600-6143.2011.03785.x. Epub 2011 Oct 12.</citation>
    <PMID>21992533</PMID>
  </reference>
  <reference>
    <citation>Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, Hutchinson JA, Vogt K, Schlickeiser S, Kverneland AH, Meisel C, Volk HD, Sawitzki B. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res. 2013 Oct 25;2(1):17. doi: 10.1186/2047-1440-2-17.</citation>
    <PMID>24160259</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ramsey Hachem</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>donor-specific HLA antibodies</keyword>
  <keyword>lung transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

